• Disease
  • Lung
  • Lung Cancer
  • Julie Renee Brahmer

    Prominent publications by Julie Renee Brahmer

    KOL Index score: 23168

    BACKGROUND: Nivolumab plus ipilimumab showed promising efficacy for the treatment of non-small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit. In this part of an open-label, multipart, phase 3 trial, we examined progression-free survival with nivolumab plus ipilimumab versus chemotherapy among patients with a high tumor mutational burden (≥10 mutations per megabase).

    METHODS: We enrolled patients with stage IV or ...

    Also Ranks for: Nivolumab Ipilimumab |  tumor mutational burden |  chemotherapy patients |  lung cancer |  progressionfree survival
    KOL Index score: 20847

    BACKGROUND: In an early-phase study involving patients with advanced non-small-cell lung cancer (NSCLC), the response rate was better with nivolumab plus ipilimumab than with nivolumab monotherapy, particularly among patients with tumors that expressed programmed death ligand 1 (PD-L1). Data are needed to assess the long-term benefit of nivolumab plus ipilimumab in patients with NSCLC.

    METHODS: In this open-label, phase 3 trial, we randomly assigned patients with stage IV or recurrent ...

    Also Ranks for: Ipilimumab Nivolumab |  chemotherapy patients |  pdl1 expression level |  antineoplastic agents |  median duration
    KOL Index score: 19890

    INTRODUCTION: For patients with non-small cell lung cancer (NSCLC) to benefit from ALK inhibitors, sensitive and specific detection of ALK genomic rearrangements is needed. ALK break-apart fluorescence in situ hybridization (FISH) is the U.S. Food and Drug Administration approved and standard-of-care diagnostic assay, but identification of ALK rearrangements by other methods reported in NSCLC cases that tested negative for ALK rearrangements by FISH suggests a significant false-negative ...

    Also Ranks for: Comprehensive Genomic Profiling |  alk rearrangements |  situ hybridization |  cell lung |  patients nsclc
    KOL Index score: 19756

    Background: Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a favorable safety profile with the anti-programmed death-1 antibody nivolumab versus docetaxel in patients with previously treated advanced squamous (CheckMate 017) and nonsquamous (CheckMate 057) NSCLC. We report results from ≥3 years' follow-up, including subgroup analyses of patients with liver metastases, ...

    Also Ranks for: Liver Metastases |  docetaxel patients |  nivolumab versus |  treated advanced |  checkmate 017
    KOL Index score: 19368

    BACKGROUND: Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for NSCLC.

    METHODS: The open-label, phase 1, multicohort study (CheckMate 012) cohorts reported here were enrolled at eight US academic centres. Eligible patients were aged 18 years or older with histologically or cytologically confirmed ...

    Also Ranks for: Nivolumab Ipilimumab |  patients nsclc |  2 weeks |  lung carcinoma |  phase 1
    KOL Index score: 18889

    PURPOSE: CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non-small-cell lung cancer (NSCLC). We assessed the association of efficacy with programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB).

    PATIENTS AND METHODS: Two hundred eighty-eight patients with previously untreated, recurrent stage IIIB/IV NSCLC received nivolumab 3 mg/kg every 2 ...

    Also Ranks for: Patients Tmb |  programmed death ligand |  1 l1 |  cell lung |  tumor mutational
    KOL Index score: 18575

    PURPOSE: To characterize the effect of concurrent stereotactic radiosurgery-stereotactic radiation therapy (SRS-SRT) and immune checkpoint inhibitors on patient outcomes and safety in patients with brain metastases (BMs).

    METHODS AND MATERIALS: We retrospectively identified metastatic non-small cell lung cancer, melanoma, and renal cell carcinoma patients who had BMs treated with SRS-SRT from 2010 to 2016 without prior whole-brain radiation therapy. We included SRS-SRT patients who were ...

    Also Ranks for: Immune Checkpoint Inhibitors |  cell lung |  concurrent ici |  stereotactic radiosurgery |  brain metastases
    KOL Index score: 18512

    BACKGROUND: In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer (NSCLC) with a programmed cell death-ligand 1 (PD-L1) tumour proportion score of 50% or greater (PD-L1-positive). Here we report the prespecified exploratory endpoint of pembrolizumab versus chemotherapy on patient-reported outcomes (PROs).

    METHODS: In this multicentre, ...

    Also Ranks for: Pembrolizumab Chemotherapy |  3 trial |  baseline week |  time deterioration |  quality life
    KOL Index score: 18093

    BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity.

    METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had progressed during or after platinum-based doublet chemotherapy to receive nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks or docetaxel at a ...

    Also Ranks for: Nivolumab Docetaxel |  cell lung |  1 year |  advanced nonsquamous |  39 95
    KOL Index score: 17232

    PURPOSE: In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor proportion score of 50% or greater and without EGFR/ALK aberrations. We report an updated OS and tolerability analysis, including analyses adjusting for potential bias ...

    Also Ranks for: Chemotherapy Pembrolizumab |  updated analysis |  humanized antineoplastic agents |  versus platinum |  cell lung
    KOL Index score: 16727

    BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population.

    METHODS: We randomly assigned 272 patients to receive ...

    Also Ranks for: Nivolumab Docetaxel |  cell lung |  advanced squamous |  survival response rate |  hazard ratio
    KOL Index score: 16283

    OBJECTIVES: Most lung cancer diagnoses occur in elderly patients, who are underrepresented in clinical trials. We present a pooled analysis of safety and efficacy in elderly patients (≥75 years) who received pembrolizumab (a programmed death 1 inhibitor) for advanced non-small-cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1)‒positive tumors.

    METHODS: The pooled analysis included patients aged ≥18 years with advanced NSCLC with PD-L1-positive tumors from the KEYNOTE-010 ...

    Also Ranks for: Elderly Patients |  pooled analysis |  cell lung |  pembrolizumab monotherapy |  advanced nsclc
    KOL Index score: 15977

    BACKGROUND: In the phase III CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; ≥10 mutations/megabase).

    AIM: To evaluate patient-reported outcomes (PROs) in this population.

    METHODS: Disease-related symptoms and general health status were assessed using the validated PRO questionnaires Lung ...

    Also Ranks for: Lung Cancer |  versus chemotherapy |  nivolumab ipilimumab |  checkmate 227 trial |  phase iii
    KOL Index score: 15805

    INTRODUCTION: In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified descriptive analysis). We report results with minimum 4 years' follow-up.

    METHODS: Adults with previously untreated stage IV or recurrent NSCLC were randomized (1:1:1) to nivolumab plus ipilimumab, nivolumab, or chemotherapy (PD-L1 ≥1%); or to ...

    Also Ranks for: Nivolumab Ipilimumab |  advanced nsclc |  chemotherapy patients |  1 l1 |  year outcomes
    KOL Index score: 15669

    Purpose Provide evidence-based recommendations updating the 2015 ASCO guideline on systemic therapy for patients with stage IV non-small-cell lung cancer (NSCLC). Methods The ASCO NSCLC Expert Panel made recommendations based on a systematic review of randomized controlled trials from February 2014 to December 2016 plus the Cancer Care Ontario Program in Evidence-Based Care's update of a previous ASCO search. Results This guideline update reflects changes in evidence since the previous ...

    Also Ranks for: Systemic Therapy |  guideline update |  monoclonal antibodies |  cell lung |  clinical oncology


    Julie Renee Brahmer: Influence Statistics

    Sample of concepts for which Julie Renee Brahmer is among the top experts in the world.
    Concept World rank
    females progressionfree survival #1
    12 weeks nivolumab #1
    baseline tumor cavitation #1
    human plasma gefitinib #1
    impact cip development #1
    analysis clinical benefit #1
    bms936558 ono4538 #1
    sbrt ici #1
    clinicians singleagent atezolizumab #1
    pfs skin metastasis #1
    4year survival 14 #1
    srssrt #1
    development multisystem iraes #1
    cancer patients gefitinib #1
    jnj757 1 #1
    dermatitis colitis #1
    pembrolizumab elderly patients #1
    multidisciplinary input patients #1
    1 median duration #1
    pemetrexed itraconazole #1
    patients maintenance bv #1
    chronic ici #1
    328 nivolumab #1
    nsclc checkmate #1
    gefitinib tk inhibitors #1
    ipilimumab 6 weeks #1
    bv induction #1
    bv maintenance nonprogressors #1
    additional surgical details #1
    hrqol questionnaires assessments #1
    clinical studies nivolumab #1
    ca209003 study #1
    elderly patients pdl1 #1
    advanced nsclc addition #1
    metformin advanced nsclc #1
    pdl1 nivolumab #1
    pcb hbp #1
    pfs females #1
    resectable lung #1
    patients driver alterations #1
    steroidrefractory icipneumonitis january #1
    pdgf nsclc #1
    median age 635 #1
    kras mutants 95 #1
    agents iraes #1
    pancreatic cancer medulloblastoma #1
    jnj64041757 jnj757 #1
    survival pcb #1
    steroidrefractory icipneumonitis #1
    keynote010 keynote024 #1

    Key People For Lung Cancer

    Top KOLs in the world
    Ahmedin M Jemal
    united states breast cancer addis ababa
    Rebecca L Siegel
    united states colorectal cancer incidence rates
    Freddie Ian Bray
    cancer incidence nordic countries mortality rates
    Jacques Ferlay
    cancer incidence global burden latin america
    Adi F Gazdar
    lung cancer cell lines aberrant methylation
    Frances Alice Shepherd
    lung cancer small cell adjuvant chemotherapy

    Julie Renee Brahmer:Expert Impact

    Concepts for whichJulie Renee Brahmerhas direct influence:Lung cancer,  Cell lung,  Small cell,  Advanced nsclc,  Neoadjuvant nivolumab,  Clinical activity,  Nivolumab docetaxel.

    Julie Renee Brahmer:KOL impact

    Concepts related to the work of other authors for whichfor which Julie Renee Brahmer has influence:Lung cancer,  Immune checkpoint inhibitors,  Small cell,  Tumor microenvironment,  Pdl1 expression,  Monoclonal antibodies,  Nsclc patients.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA | Bloomberg-Kimmel Institute for Cancer Immunotherapy, , Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, , Balt